PMID- 21502808
OWN - NLM
STAT- MEDLINE
DCOM- 20111003
LR  - 20200930
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Linking)
VI  - 11
IP  - 11
DP  - 2011 Jun 1
TI  - An experimental study of dendritic cells transfected with cancer stem-like cells 
      RNA against 9L brain tumors.
PG  - 974-80
AB  - Cancer stem cells are defined as a subpopulation of cancer cells with the 
      capacity to self-renew and differentiate, which may play critical roles in tumor 
      initiation, progress and resistance to current treatments. It has been reported 
      that Dendritic cells (DCs) transfected with total tumor RNA could induce strong 
      antitumor T-cell responses both in vivo and in vitro. In the study, we 
      investigated the characteristics of 9L tumor spheres, and evaluated the antitumor 
      effects of DCs transfected with 9L tumor spheres RNA in vivo. The results showed 
      that 9L tumor spheres have the properties of cancer stem cells, and the majority 
      of 9L cells were positive for CD133 and nestin. DCs transfected with 9L tumor 
      spheres RNA can significantly inhibit glioma growth and prolong the survival of 
      9L glioma-bearing rats. These results demonstrated that 9L cancer stem like cells 
      were enriched in tumor spheres, and they were a part of CD133+ cells, DCs 
      transfected with cancer stem cells RNA may be an effective therapy for glioma.
FAU - Xiao, Zong-yu
AU  - Xiao ZY
AD  - Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Tang, Hao
AU  - Tang H
FAU - Xu, Zhi-min
AU  - Xu ZM
FAU - Yan, Zhong-jie
AU  - Yan ZJ
FAU - Li, Peng
AU  - Li P
FAU - Cai, Ying-qian
AU  - Cai YQ
FAU - Jiang, Xiao-dan
AU  - Jiang XD
FAU - Xu, Ru-xiang
AU  - Xu RX
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110601
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Culture Media)
RN  - 0 (Glycoproteins)
RN  - 0 (Intermediate Filament Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nes protein, rat)
RN  - 0 (Nestin)
RN  - 0 (Peptides)
RN  - 0 (Prom1 protein, rat)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 63231-63-0 (RNA)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - AC133 Antigen
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Brain Neoplasms/genetics/*pathology/therapy
MH  - Cancer Vaccines/*genetics/therapeutic use
MH  - Cell Culture Techniques
MH  - Cell Line, Tumor
MH  - Culture Media
MH  - Dendritic Cells/metabolism/*transplantation
MH  - Epidermal Growth Factor/pharmacology
MH  - Fibroblast Growth Factor 2/pharmacology
MH  - Gliosarcoma/genetics/*pathology/therapy
MH  - Glycoproteins/metabolism
MH  - Interferon-gamma/blood
MH  - Intermediate Filament Proteins/metabolism
MH  - Kaplan-Meier Estimate
MH  - Neoplastic Stem Cells/drug effects/immunology/*pathology
MH  - Nerve Tissue Proteins/metabolism
MH  - Nestin
MH  - Peptides/metabolism
MH  - RNA/*immunology
MH  - Rats
MH  - Transfection
MH  - Xenograft Model Antitumor Assays
EDAT- 2011/04/20 06:00
MHDA- 2011/10/04 06:00
CRDT- 2011/04/20 06:00
PHST- 2011/04/20 06:00 [entrez]
PHST- 2011/04/20 06:00 [pubmed]
PHST- 2011/10/04 06:00 [medline]
AID - 15705 [pii]
AID - 10.4161/cbt.11.11.15705 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2011 Jun 1;11(11):974-80. doi: 10.4161/cbt.11.11.15705. Epub 
      2011 Jun 1.